Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: Disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment

Veterinary Dermatology

Volumn 21, Issue 4, 2010, Pages 373-382

  Mauldin, Elizabeth A ^a   Morris, Daniel O ^a   Brown, Dorothy C ^a   Casal, Margret L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYCLOSPORIN; FATTY ACID; HYDROXYCHLOROQUINE; MONOCLONAL ANTIBODY;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; PATHOLOGY; SKIN LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; CYCLOSPORINE; DOG DISEASES; DOGS; FATTY ACIDS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE;

CANIS FAMILIARIS;

EID: 77954376176     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2010.00867.x     Document Type: Article

References (48)

1. Bryden SL, White SD, Dunston SM. Clinical, histopathological and immunological characteristics of exfoliative cutaneous lupus erythematosus in 25 German short-haired pointers. Veterinary Dermatology 2005, 16:239-52.
2. Gross TL, Ihrke PJ. Ulcerative dermatosis of Shetland Sheepdog and Collie. Current Veterinary Therapy XII: Small Animal Practice 1995, 639-70. Bonagura JD, Kirk KW. In, eds, Philadelphia, PA, W.B. Saunders
3. Gross TL, Ihrke PJ, Walder EJ. Interface diseases of the dermal-epidermal junction. Skin Diseases of the Dog and Cat. Clinical and Histopathologic Diagnosis 2005, 49-74. In, 2nd edn, Ames, IA, Blackwell Science, Ltd
4. Jackson HA. Eleven cases of vesicular cutaneous lupus erythematosus in Shetland sheepdogs and rough collies: clinical management and prognosis. Veterinary Dermatology 2004, 15:37-41.
5. Jackson HA, Olivry T. Ulcerative dermatosis of the Shetland sheepdog and rough collie dog may represent a novel vesicular variant of cutaneous lupus erythematosus. Veterinary Dermatology 2001, 12:19-27.
6. Olivry T, Savary KC, Murphy KM. Bullous systemic lupus erythematosus (type I) in a dog. Veterinary Record 1999, 145:165-9.
7. Scott DW, Walton DK, Manning TO. Canine systemic lupus I. Systemic lupus erythematosus. Journal of the American Animal Hospital Association 1983, 19:461-79.
8. Scott DW, Griffin CE. Immune-mediated disorders. Muller and Kirk's Small Animal Dermatology 2001, 701-17. In, 6th edn, Philadelphia, PA, W.B. Saunders
9. Vroom MW, Theaker MJ, Rest JR. Lupoid dermatosis in five German short-haired pointers. Veterinary Dermatology 1995, 6:93-8.
10. Theaker AJ, Rest JR. Lupoid dermatosis in a German short haired pointer. Veterinary Record 1992, 131:495.
11. Stone M. Systemic lupus erythematosus. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat 2005, 1952-7. Ettinger SJFeldman EC. In, eds, 6th edn, St. Louis, MO, Elsevier/Saunders
12. Costner MI, Sontheimer RD. Lupus erythematosus. Fitzpatrick's Dermatology in General Medicine 2003, 1677-93. Freedberg IM, Eisen AZWolff K. In, eds, 6th edn, New York, McGraw-Hill
13. Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatologic Clinics 2002, 20:373-85.
14. Werth VP. Cutaneous lupus: insights into pathogenesis and disease classification. Bulletin of the NYU Hospital for Joint Diseases 2007, 65:200-4.
15. Werth V. Current treatment of cutaneous lupus erythematosus. Dermatology Online Journal 2001, 7:2.
16. Font A, Bardagi M, Mascort J. Treatment with oral cyclosporin A of a case of vesicular cutaneous lupus erythematosus in a rough collie. Veterinary Dermatology 2006, 17:440-2.
17. Guaguere E, Steffan J, Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Veterinary Dermatology 2004, 15:61-74.
18. Hansen B, Lascelles B, Keene B. Evaluation of an accelerometer for at-home monitoring of spontaneous activity in dogs. American Journal of Veterinary Research 2007, 68:468-75.
19. Sontheimer RD. The lexicon of cutaneous lupus erythematosus - a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997, 6:84-95.
20. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1982, 25:1271-7.
21. Lin JH, Dutz JP, Sontheimer RD. Pathophysiology of cutaneous lupus erythematosus. Clinical Reviews in Allergy and Immunology 2007, 33:85-106.
22. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clinical Dermatology 2006, 24:348-62.
23. Johnston SD, Root Kustritz MV, Olson PS. Sexual differentiation and normal anatomy of the dog. Canine and Feline Theriogenology 2001, 275-86. In, 1st edn, Philadelphia, PA, W.B. Saunders
24. Soares PM, Borba EF, Bonfa E. Gonad evaluation in male systemic lupus erythematosus. Arthritis and Rheumatism 2007, 56:2352-61.
25. Geva E, Lerner-Geva L, Burke M. Undiagnosed systemic lupus erythematosus in a cohort of infertile women. American Journal of Reproductive Immunology 2004, 51:336-40.
26. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy 2007, 20:160-74.
27. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002, 11:71-81.
28. Wozniacka A, McCauliffe DP. Optimal use of antimalarials in treating cutaneous lupus erythematosus. American Journal of Clinical Dermatology 2005, 6:1-11.
29. Lansimies E, Laaksonen AL, Juva K. Acute cardiotoxicity of chloroquine and hydroxychloroquine in dogs. Annales Medicinae Experimentalis et Biologiae Fenniae 1971, 49:45-8.
30. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. American Journal of Medicine 1983, 75:40-5.
31. Olivry T, Rivierre C, Jackson HA. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Veterinary Dermatology 2002, 13:77-87.
32. Olivry T, Steffan J, Fisch RD. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002, 221:370-7.
33. Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Veterinary Dermatology 2006, 17:3-16.
34. Steffan J, Parks C, Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. Journal of the American Veterinary Medical Association 2005, 226:1855-63.
35. Mascarell L, Truffa-Bachi P. New aspects of cyclosporin a mode of action: from gene silencing to gene up-regulation. Mini Reviews in Medicinal Chemistry 2003, 3:205-14.
36. Losa Garcia JE, Mateos Rodriguez F, Jimenez Lopez A. Action of cyclosporin A on mononuclear phagocytes. Journal of Investigative Allergology and Clinical Immunology 1996, 6:222-31.
37. Pardo J, Mercader P, Mahiques L. Infliximab in the management of severe pemphigus vulgaris. British Journal of Dermatology 2005, 153:222-3.
38. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. British Journal of Dermatology 2005, 153:448-9.
39. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005, 19:47-57.
40. Sacher C, Rubbert A, Konig C. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. Journal of the American Academy of Dermatology 2002, 46:113-5.
41. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004, 74:245-7.
42. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005, 25:1181-92.
43. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Journal of Dermatological Treatment 2004, 15:280-94.
44. Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Archives of Dermatology 2005, 141:680-2.
45. Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opinion on Drug Safety 2008, 7:411-9.
46. Ramos-Casals M, Brito-Zeron P, Munoz S. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-51.
47. Ramos-Casals M, Brito-Zeron P, Soto MJ. Autoimmune diseases induced by TNF-targeted therapies. Best Practice & Residential Clinical Rheumatology 2008, 22:847-61.
48. Aringer M, Graninger WB, Steiner G. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis and Rheumatism 2004, 50:3161-9.